An interventional study of LineMatrix® Biological Vascular Graft and GORE-INTERING® in Arteriovenous Graft, sponsored by Longhua Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Longhua Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.
Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 23rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 12 that started in 2025, is one of 40 with no phase, reaches primary completion later than 24 of the 35 other live ones, and was the 112th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:
CSL Behring · Sites in China
Ages 18+
Vantive Health LLC · Sites in China
Ages 18–79
Tongji Hospital · Sites in China
Ages 18–65
Yunfeng Xia · Sites in China
Ages 18–75
Suzhou Alphamab Co., Ltd. · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 9 · Phase 4 18
First in 1996; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 326 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 150 across the 83 interventional studies, 250 across the 31 observational. Of the 55 that completed or were terminated, 7 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 114 have an industry lead sponsor. The 10 most frequent:
Longhua Hospital is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Longhua Hospital has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05639010Changhai HospitalEffects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study | 2026-12-31 |
| NCT07350837Tongji HospitalCAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants | 2026-12-31 |
| NCT07291154Yunfeng XiaImpact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy | 2026-12-31 |
| NCT05315141Xiangya Hospital of Central South UniversityMulticenter Cohort Study of AAV in Hunan of China | 2027-03-16 |
| NCT07303179The First People's Hospital of YunnanExercise Rehabilitation for Functional Impairment in Maintenance Hemodialysis Patients | 2027-06-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 114 studies in Kidney Failure, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is planned to be conducted at multiple centers, with an intended enrollment of 326 subjects. Protocol-eligible subjects will be randomized in a 1:1 ratio to either the investigational group or the control group. The investigational group will receive a Biological Vascular Graft(LineMatrix®) manufactured by Humatrix Medical Technology (Suzhou) Co., LTD, while the control group will receive an arteriovenous graft (GORE-INTERING®) manufactured by W.L. Gore \& Associates, Inc. The primary endpoints are the Primary patency rate at 6 months postoperatively and the Cumulative Patency Rate at 12 Months postoperatively. Subjects will undergo follow-up during the screening period, at the time of AVG procedure, and at 1 month, 3 months, 6 months, and 12 months post-operatively. Safety and efficacy parameters will be observed and recorded during and after the surgery to evaluate the safety and effectiveness of the LineMatrix® Biological Vascular Graft for the creation of arteriovenous graft in patients with end-stage renal disease (ESRD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: LineMatrix® Biological Vascular Graft
Device: GORE-INTERING®
LineMatrix® Biological Vascular Graft
GORE-INTERING®
Primary patency rate at 6 months postoperatively
Primary Patency Rate is defined as the proportion of subjects who have not experienced any of the following events from the date of vascular access creation through 6 months post-operatively: thrombosis, or any intervention performed to promote, maintain, or re-establish patency (e.g., angioplasty).
Time frame: 6 months
Cumulative Patency Rate at 12 Months Postoperatively
Cumulative Patency Rate is defined as the proportion of subjects whose vascular access has not been abandoned from the date of vascular access creation through 12 months post-operatively.
Time frame: 12 months
Primary patency rate at 3,12 months postoperatively
Primary Patency Rate is defined as the proportion of subjects who have not experienced any of the following events from the date of vascular access creation through 3,12 months post-operatively: thrombosis, or any intervention performed to promote, maintain, or re-establish patency (e.g., angioplasty).
Time frame: 3,12 months
Cumulative Patency Rate at 3,6 Months Postoperatively
Cumulative Patency Rate is defined as the proportion of subjects whose vascular access has not been abandoned from the date of vascular access creation through 3, 6 months post-operatively.
Time frame: 3,6 months
Surgical success rate
Surgical success rate is defined as the successful completion of the arteriovenous graft (AVG) surgery using the investigational device, without any device-related serious adverse events occurring during the perioperative period.
Time frame: 30 days
Time to First Cannulation
Time to First Cannulation is defined as the interval from the AVG procedure to the first hemodialysis session performed using the arteriovenous graft.
Time frame: 12 months
Device Performance Evaluation
I.Suturability Excellent: Needle passes through vessel with light touch and no deformation after arterial suturing; Good: Needle passes through vessel with light force and shows deformation after arterial suturing but can continue to be used; Poor: Needle passes through vessel with force and shows severe deformation after arterial suturing and cannot continue to be used. II.Anastomotic bleeding No: No visible blood leakage at anastomosis; Yes: Visible blood leakage at anastomosis. III.Post-cannulation hemostasis Excellent: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is \<10 min. Good: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is 10-15 min. Poor: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is \>15 min, or additional hemostatic measures are required.
Time frame: 12 months
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 22 months is close to that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Longhua Hospital